Differential diagnosis of pulmonary carcinoma following head and neck cancer by genetic analysis

Clinical Cancer Research

Volumn 15, Issue 3, 2009, Pages 980-985

  Geurts, T W ^c   Van Velthuysen, M L F ^b   Broekman, F ^d   Van Huysduynen, T Hooft ^d   Van Den Brekel, M W M ^a,c   Van Zandwijk, N ^a   Van Tinteren, H ^a   Nederlof, P ^b   Balm, A J M ^a,c   Brakenhoff, R H ^d,e  

^a Department of Head Neck Oncology and Surgery ^*  (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISTANT METASTASIS; FEMALE; GENE EXPRESSION; GENE LOSS; GENE MUTATION; GENETIC ANALYSIS; HEAD AND NECK CARCINOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SECOND CANCER; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, SECOND PRIMARY;

EID: 61349092379     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1968     Document Type: Article

References (18)

1. Larson JT, Adams GL, Fattah HA. Survival statistics for multiple primaries in head and neck cancer. Otolaryngol Head Neck Surg 1990;103:14-24.
2. Leon X, Quer M, Diez S, Orus C, Lopez-Pousa A, Burgues J. Second neoplasm in patients with head and neck cancer. Head Neck 1999;21:204-10.
3. Rafferty MA, O'Dwyer TP. Secondary primary malignancies in head and neck squamous cell carcinoma. J Laryngol Otol 2001;115:988-91.
4. Calhoun KH, Fulmer P, Weiss R, Hokanson JA. Distant metastases from head and neck squamous cell carcinomas. Laryngoscope 1994;104:1199 -205.
5. Henschke CI, Wisnivesky JP, Yankelevitz DF, Miettinen OS. Small stage I cancers of the lung: genuineness and curability. Lung Cancer 2003;39:327-30.
6. Wisnivesky JP,Yankelevitz D, Henschke CI. The effect of tumor size on curability of stage I non-small cell lung cancers. Chest 2004;126:761 -5.
7. Bach PB, KelleyMJ, Tate RC, Mc Crory DC. Screening for lung cancer-a review of the current literature. Chest 2003;123:72 -82s.
8. Geurts TW, Nederlof PM, van den Brekel MW, et al. Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary? Clin Cancer Res 2005;11:6608-14.
9. Califano J, Leong PL, Koch WM, et al. Second esoph- ageal tumors in patients with head and neck squa- mous cell carcinoma: an assessment of clonal relationships. Clin Cancer Res1999;5:1862-7.
10. van Oijen MG, Leppers Vd Straat FG,Tilanus MG, Slootweg PJ. The origins of multiple squamous cell carcinomas in the aerodigestive tract. Cancer 2000; 88:884-93.
11. van Houten VM, Tabor MP, Brekel van den MWM, et al. Molecular assays for the diagnosis of minimal residual head and neck cancer: methods, reliability, pitfalls, and solutions. Clin Cancer Res 2000;6:3803 -16.
12. Tabor MP, van HoutenVM, KummerJA, et al. Discordance of genetic alterations between primary head and neck tumors and corresponding metastases associated with mutational status of theTP53 gene. Genes Chromosomes Cancer 2002;33:168-77.
13. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253: 49 -53.
14. Skotheim RI, Diep CB, KraggerudSM,Jakobsen KS, Lothe RA. Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA. Cancer Genet Cytogenet 2001;27:64-70.
15. van Houten VM, Tabor MP, Brekel van den MWM, et al. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. J Pathol 2002;198: 476 -86.
16. Leong PP, Rezai B, Koch WM, et al. Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma.J Natl Cancer Inst 1998;90:972-7.
17. Campling BG, el-Deiry WS. Clinical implications of p53 mutations in lung cancer. Methods Mol Med 2003;75:53 -77.
18. Sjogren EV, Snijder S, van Beekum J, Baatenburg de Jong RJ. Second malignant neoplasia in early (TIS- T1) glottic carcinoma. Head Neck 2006;28:501 -7.